-
The AHEAD Study - with participants in the Orlando region - examines whether the newly approved drug lecanemab can prevent or at least delay the appearance of Alzheimer's symptoms.
-
Private equity-backed Headlands Research heralded its COVID vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
-
The medical director at Accel Research Sites in DeLand expects a shot for RSV to be available by the new year and a combination RSV, COVID and flu shot by next fall.
-
The only Lyme vaccine for humans was pulled off the U.S. market in 2002 from lack of demand, leaving people to rely on bug spray and tick checks.
-
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for COVID. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
-
Drug manufacturers invested in Russia’s pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion.
-
About 200 people are expected to be enrolled in the UF Health component of the trial, with about 15,000 participating nationwide
-
Pfizer studied a lower dose of its vaccine in more than 2,200 kindergartners and elementary school-aged kids. They developed coronavirus-fighting antibody levels as strong as teens and young adults.
-
When a new drug is up for FDA approval, trials may be held not only in the U.S. but other countries too. A study looks at global availability after approval. Big Pharma disagrees with the findings.
-
Parents who have enrolled their children in these studies say the risk is worth it for the greater good.